Stoke-on-Trent

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Multiple myeloma5 trials

Phase

• Phase 33 trials
• Phase 22 trials

Status

• Active, not recruiting3 trials
• Completed2 trials

Lead sponsor

• GlaxoSmithKline5 trials

Running trials

• Active, not recruiting

  Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

  NCT04484623· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

  NCT04246047· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  NCT04162210· Phase 3· GlaxoSmithKline· Source

Closed trials

• Completed

  Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05064358· Phase 2· GlaxoSmithKline· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody

  NCT03525678· Phase 2· GlaxoSmithKline· Source